Literature DB >> 31969375

The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.

Sandra Cristea1,2, Garry L Coles1,2, Daniel Hornburg2, Maya Gershkovitz1,2, Julia Arand1,2, Siqi Cao1,2, Triparna Sen3, Stuart C Williamson1,2,4, Jun W Kim1,2, Alexandros P Drainas1,2, Andrew He1,2, Laurent Le Cam5, Lauren Averett Byers3, Michael P Snyder2, Kévin Contrepois2, Julien Sage6,2.   

Abstract

Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with dismal survival rates. While kinases often play key roles driving tumorigenesis, there are strikingly few kinases known to promote the development of SCLC. Here, we investigated the contribution of the MAPK module MEK5-ERK5 to SCLC growth. MEK5 and ERK5 were required for optimal survival and expansion of SCLC cell lines in vitro and in vivo. Transcriptomics analyses identified a role for the MEK5-ERK5 axis in the metabolism of SCLC cells, including lipid metabolism. In-depth lipidomics analyses showed that loss of MEK5/ERK5 perturbs several lipid metabolism pathways, including the mevalonate pathway that controls cholesterol synthesis. Notably, depletion of MEK5/ERK5 sensitized SCLC cells to pharmacologic inhibition of the mevalonate pathway by statins. These data identify a new MEK5-ERK5-lipid metabolism axis that promotes the growth of SCLC. SIGNIFICANCE: This study is the first to investigate MEK5 and ERK5 in SCLC, linking the activity of these two kinases to the control of cell survival and lipid metabolism. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31969375      PMCID: PMC7073279          DOI: 10.1158/0008-5472.CAN-19-1027

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.

Authors:  Duy Nguyen; Clara Lemos; Lars Wortmann; Knut Eis; Simon J Holton; Ulf Boemer; Dieter Moosmayer; Uwe Eberspaecher; Joerg Weiske; Christian Lechner; Stefan Prechtl; Detlev Suelzle; Franziska Siegel; Florian Prinz; Ralf Lesche; Barbara Nicke; Katrin Nowak-Reppel; Herbert Himmel; Dominik Mumberg; Franz von Nussbaum; Carl F Nising; Marcus Bauser; Andrea Haegebarth
Journal:  J Med Chem       Date:  2019-01-09       Impact factor: 7.446

Review 2.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Authors:  Charles M Rudin; John T Poirier; Lauren Averett Byers; Caroline Dive; Afshin Dowlati; Julie George; John V Heymach; Jane E Johnson; Jonathan M Lehman; David MacPherson; Pierre P Massion; John D Minna; Trudy G Oliver; Vito Quaranta; Julien Sage; Roman K Thomas; Christopher R Vakoc; Adi F Gazdar
Journal:  Nat Rev Cancer       Date:  2019-05       Impact factor: 60.716

Review 3.  Unravelling the biology of SCLC: implications for therapy.

Authors:  Joshua K Sabari; Benjamin H Lok; James H Laird; John T Poirier; Charles M Rudin
Journal:  Nat Rev Clin Oncol       Date:  2017-05-23       Impact factor: 66.675

4.  CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Authors:  Triparna Sen; Pan Tong; C Allison Stewart; Sandra Cristea; Aly Valliani; David S Shames; Abena B Redwood; You Hong Fan; Lerong Li; Bonnie S Glisson; John D Minna; Julien Sage; Don L Gibbons; Helen Piwnica-Worms; John V Heymach; Jing Wang; Lauren Averett Byers
Journal:  Cancer Res       Date:  2017-05-10       Impact factor: 12.701

5.  Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility.

Authors:  Sarah K Denny; Dian Yang; Chen-Hua Chuang; Jennifer J Brady; Jing Shan Lim; Barbara M Grüner; Shin-Heng Chiou; Alicia N Schep; Jessika Baral; Cécile Hamard; Martine Antoine; Marie Wislez; Christina S Kong; Andrew J Connolly; Kwon-Sik Park; Julien Sage; William J Greenleaf; Monte M Winslow
Journal:  Cell       Date:  2016-06-30       Impact factor: 41.582

6.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Authors:  Martin Peifer; Lynnette Fernández-Cuesta; Martin L Sos; Julie George; Danila Seidel; Lawryn H Kasper; Dennis Plenker; Frauke Leenders; Ruping Sun; Thomas Zander; Roopika Menon; Mirjam Koker; Ilona Dahmen; Christian Müller; Vincenzo Di Cerbo; Hans-Ulrich Schildhaus; Janine Altmüller; Ingelore Baessmann; Christian Becker; Bram de Wilde; Jo Vandesompele; Diana Böhm; Sascha Ansén; Franziska Gabler; Ines Wilkening; Stefanie Heynck; Johannes M Heuckmann; Xin Lu; Scott L Carter; Kristian Cibulskis; Shantanu Banerji; Gad Getz; Kwon-Sik Park; Daniel Rauh; Christian Grütter; Matthias Fischer; Laura Pasqualucci; Gavin Wright; Zoe Wainer; Prudence Russell; Iver Petersen; Yuan Chen; Erich Stoelben; Corinna Ludwig; Philipp Schnabel; Hans Hoffmann; Thomas Muley; Michael Brockmann; Walburga Engel-Riedel; Lucia A Muscarella; Vito M Fazio; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle A M Heideman; Peter J F Snijders; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; John Field; Steinar Solberg; Odd Terje Brustugun; Marius Lund-Iversen; Jörg Sänger; Joachim H Clement; Alex Soltermann; Holger Moch; Walter Weder; Benjamin Solomon; Jean-Charles Soria; Pierre Validire; Benjamin Besse; Elisabeth Brambilla; Christian Brambilla; Sylvie Lantuejoul; Philippe Lorimier; Peter M Schneider; Michael Hallek; William Pao; Matthew Meyerson; Julien Sage; Jay Shendure; Robert Schneider; Reinhard Büttner; Jürgen Wolf; Peter Nürnberg; Sven Perner; Lukas C Heukamp; Paul K Brindle; Stefan Haas; Roman K Thomas
Journal:  Nat Genet       Date:  2012-09-02       Impact factor: 38.330

7.  MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.

Authors:  James W Antoon; Elizabeth C Martin; Rongye Lai; Virgilo A Salvo; Yan Tang; Ashley M Nitzchke; Steven Elliott; Seung Yoon Nam; Wei Xiong; Lyndsay V Rhodes; Bridgette Collins-Burow; Odile David; Guandi Wang; Bin Shan; Barbara S Beckman; Kenneth P Nephew; Matthew E Burow
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

8.  Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC).

Authors:  Ting Zhou; Jianhua Zhan; Wenfeng Fang; Yuanyuan Zhao; Yunpeng Yang; Xue Hou; Zhonghan Zhang; Xiaobo He; Yaxiong Zhang; Yan Huang; Li Zhang
Journal:  BMC Cancer       Date:  2017-04-14       Impact factor: 4.430

Review 9.  Impact of ERK5 on the Hallmarks of Cancer.

Authors:  Barbara Stecca; Elisabetta Rovida
Journal:  Int J Mol Sci       Date:  2019-03-21       Impact factor: 5.923

10.  Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status.

Authors:  Sana Belkahla; Abrar Ul Haq Khan; Delphine Gitenay; Catherine Alexia; Claire Gondeau; Dang-Nghiem Vo; Stefania Orecchioni; Giovanna Talarico; Francesco Bertolini; Guillaume Cartron; Javier Hernandez; Martine Daujat-Chavanieu; Nerea Allende-Vega; Martin Villalba Gonzalez
Journal:  Oncotarget       Date:  2017-12-14
View more
  21 in total

Review 1.  Small-cell lung cancer.

Authors:  Charles M Rudin; Elisabeth Brambilla; Corinne Faivre-Finn; Julien Sage
Journal:  Nat Rev Dis Primers       Date:  2021-01-14       Impact factor: 52.329

2.  Applications of Lipidomics in Tumor Diagnosis and Therapy.

Authors:  Yuping Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk.

Authors:  Valentina Lukinović; Simone Hausmann; Gael S Roth; Clement Oyeniran; Tanveer Ahmad; Ning Tsao; Joshua R Brickner; Alexandre G Casanova; Florent Chuffart; Ana Morales Benitez; Jessica Vayr; Rebecca Rodell; Marianne Tardif; Pascal W T C Jansen; Yohann Couté; Michiel Vermeulen; Pierre Hainaut; Pawel K Mazur; Nima Mosammaparast; Nicolas Reynoird
Journal:  Cancer Discov       Date:  2022-09-02       Impact factor: 38.272

4.  Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer.

Authors:  Chenchen Guo; Ruijie Wan; Yayi He; Shu-Hai Lin; Jiayu Cao; Ying Qiu; Tengfei Zhang; Qiqi Zhao; Yujia Niu; Yujuan Jin; Hsin-Yi Huang; Xue Wang; Li Tan; Roman K Thomas; Hua Zhang; Luonan Chen; Kwok-Kin Wong; Liang Hu; Hongbin Ji
Journal:  Nat Cancer       Date:  2022-04-21

5.  Untargeted metabolomics and transcriptomics identified glutathione metabolism disturbance and PCS and TMAO as potential biomarkers for ER stress in lung.

Authors:  Zijing Wang; Peng Ma; Yisa Wang; Biyu Hou; Can Zhou; He Tian; Bowen Li; Guanghou Shui; Xiuying Yang; Guifen Qiang; Chengqian Yin; Guanhua Du
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

Review 6.  Targeted Therapies and Biomarkers in Small Cell Lung Cancer.

Authors:  Hirokazu Taniguchi; Triparna Sen; Charles M Rudin
Journal:  Front Oncol       Date:  2020-05-20       Impact factor: 6.244

7.  Characteristics and clinical significance of lipid metabolism in patients with gastrointestinal stromal tumor.

Authors:  Xiaoling Liu; Jun Hu; Bende Liu
Journal:  Lipids Health Dis       Date:  2022-01-07       Impact factor: 3.876

8.  MicroRNA regulation of the proliferation and apoptosis of Leydig cells in diabetes.

Authors:  Li Hu; Shaochai Wei; Yuqi Wu; Shulin Li; Pei Zhu; Xiangwei Wang
Journal:  Mol Med       Date:  2021-09-08       Impact factor: 6.354

9.  Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations.

Authors:  Jing Yang; Xiangyun Wang; Jingli Lu; Hui Chen; Xiaochen Zhao; Chan Gao; Yuezong Bai; Qiwen Zhang; Xiaomin Fu; Xiaojian Zhang
Journal:  J Cancer       Date:  2021-06-22       Impact factor: 4.207

Review 10.  Clinical Significance and Regulation of ERK5 Expression and Function in Cancer.

Authors:  Matilde Monti; Jacopo Celli; Francesco Missale; Francesca Cersosimo; Mariapia Russo; Elisa Belloni; Anna Di Matteo; Silvia Lonardi; William Vermi; Claudia Ghigna; Emanuele Giurisato
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.